CSL Behring is one of the world's leading plasma protein biotherapeutics companies, specializing in the manufacture of therapies for the treatment of rare and serious diseases. Its line of therapies includes products for the treatment of hemophilia, von Willebrand Disease, and other bleeding disorders; immune deficiencies including primary immunodeficiency diseases (PIDD); hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. The company also operates one of the world's largest plasma collection networks, CSL Plasma.
Campaign Finance$47,920 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of CSL Behring
Names of Lobbyists
Firm Hired Amount CSL Behring $880,000
Most Frequently Disclosed Lobbying Issues
- Medicare & Medicaid,
- Fed Budget & Appropriations,
- Health Issues
Most Frequently Disclosed Bills
Bill No. Title H.R.2672 Preserving Access to Orphan Drugs Act of 2011 S.1599 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012 S.1423 Preserving Access to Orphan Drugs Act of 2011 H.R.3070 Department of Education Appropriations Act, 2012
RegulationsMentioned in 11 dockets; Submitted to 2 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "CSL Behring" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for CSL Behring
Mentions in Document Text
View all mentions data for CSL Behring
- Toggle 10 FDA Revoke the Orphan Drug Designation and Exclusivity Given to Wilate®, Manufactured by Octa Pharma, and to Refrain From Making any Orphan Drug Designations and Approval Decisions Based on Hypothetical Claims of Superiority 2011
- Toggle 1 FDA Draft Guidances Relating to the Development of Biosimilar Products; Public Hearing; Request for Comments 2011
- Toggle 1 IRS Branded Prescription Drug Fee 2011
- Toggle 1 FDA Issue a Guidance Document to Include Specific Topics on Internal Review Standards Concerning Orphan Drugs 2011
- Toggle 1 CMS Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests (CMS-5060-P) 2011
- Toggle 1 IRS Taxable Medical Devices 2012
- Toggle 1 FDA Orphan Drug Regulations 2011
- Toggle 1 CMS Medicare Program; Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2012 2011
- Toggle 1 FDA Draft Guidance for Industry: Amendment (revisions to labeling recommendations for potential risk of vCJD) to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products,” Availability 2012
- Toggle 1 FDA Draft Guidance for Industry on Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage 2012